Roche’s fenebrutinib cuts annualized MS relapse rate 55% versus comparator in Phase III trials
Roche said fenebrutinib cut the annualized multiple sclerosis relapse rate by 55% versus a comparator in Phase III trials. The company also reported reduced chronic brain inflammation, slower brain tissue loss and lower disability progression in relapsing MS trials.
1. Phase III findings
Genentech, Roche’s subsidiary, announced Phase III results showing investigational fenebrutinib reduced chronic brain inflammation versus active comparators in multiple sclerosis. In pooled relapsing MS trials, it also reduced relapses, slowed brain tissue loss and lowered disability progression; the findings are to be presented at MSToronto2026 on October 21-23.
2. Other study updates
Roche said Ocrevus maintained relapse control in children with MS and Enspryng improved recovery after attacks in MOGAD. A U.S. decision on Enspryng for MOGAD is expected in January 2027.
